FDA's zanubrutinib record expands with CLL/SLL approval detail

The FDA's cancer approvals list includes a notice stating that on January 19, 2023, the Food and Drug Administration approved zanubrutinib, marketed as Brukinsa by BeiGene USA, Inc., for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).¹

This confirms the drug's brand name and sponsor, details that were absent from the agency's separate notice on zanubrutinib's approval for Waldenström's macroglobulinemia. That earlier record, titled "FDA approves zanubrutinib for Waldenström's macroglobulinemia," remains brief and does not list an approval date, sponsor, dosing information, or trial data.

No document reviewed specifies the application type behind either approval, such as whether it followed a supplemental new drug application, nor do the records include efficacy results like response rates or progression-free survival data that may have supported the decisions.

The Waldenström's macroglobulinemia notice also does not address patient population details, prior treatment requirements, or how the approval affects existing treatment options for the rare non-Hodgkin lymphoma.

Readers seeking fuller clinical detail on either approval, including the specific trials that supported them, will need to consult the FDA's complete approval letters or prescribing information for Brukinsa, as the records reviewed here contain only brief notices.

This outlet will add further detail on the clinical basis for the Waldenström's macroglobulinemia approval, and the application pathway for the CLL/SLL approval, as additional primary source documents become available.